Clinical Trial Update: Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of liposomal irinotecan and bevacizumab for recurrent glioma. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Avastin (bevacizumab)
• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: Zhifeng Tian,MD | Conditions: Glioma | Phase 2 | Status: RECRUITING